CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

Season 10 Episode 22  ·  Mar 25, 2024, 06:00 PM

Headliner
Share
Subscribe

Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.

Share
Subscribe
Next
Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air